133 related articles for article (PubMed ID: 30848190)
1. Evaluation of Local Injection of Bevacizumab against Triple-Negative Breast Cancer Xenograft Tumors.
Jiang X; Zhang QL; Liu TG; Zhao WP; Yang M; Wang LN; Sun WL; Pan L; Luo AP; Huang JC; Gu XH
Curr Pharm Des; 2019; 25(8):862-870. PubMed ID: 30848190
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Triple-Negative Breast Cancer Tumor Growth by Electroacupuncture with Encircled Needling and Its Mechanisms in a Mice Xenograft Model.
Jiang X; Tian Y; Xu L; Zhang Q; Wan Y; Qi X; Li B; Guo J; Sun W; Luo A; Huang J; Gu X
Int J Med Sci; 2019; 16(12):1642-1651. PubMed ID: 31839752
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
[TBL] [Abstract][Full Text] [Related]
4. A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/β-catenin signaling pathway.
Xie W; Zhao H; Wang F; Wang Y; He Y; Wang T; Zhang K; Yang H; Zhou Z; Shi H; Wang J; Huang G
J Exp Clin Cancer Res; 2021 Jan; 40(1):30. PubMed ID: 33436039
[TBL] [Abstract][Full Text] [Related]
5. Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer.
Terwisscha van Scheltinga AG; Berghuis P; Nienhuis HH; Timmer-Bosscha H; Pot L; Gaykema SB; Lub-de Hooge MN; Kosterink JG; de Vries EG; Schröder CP
Eur J Cancer; 2014 Sep; 50(14):2508-16. PubMed ID: 25027745
[TBL] [Abstract][Full Text] [Related]
6. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.
Guyot M; Hilmi C; Ambrosetti D; Merlano M; Lo Nigro C; Durivault J; Grépin R; Pagès G
Oncotarget; 2017 Feb; 8(6):9174-9188. PubMed ID: 27999187
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab Radioimmunotherapy (RIT) with Accelerated Blood Clearance Using the Avidin Chase.
Yudistiro R; Hanaoka H; Katsumata N; Yamaguchi A; Tsushima Y
Mol Pharm; 2018 Jun; 15(6):2165-2173. PubMed ID: 29733658
[TBL] [Abstract][Full Text] [Related]
8. A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib.
Yamamoto J; Murata T; Tashiro Y; Higuchi T; Sugisawa N; Nishino H; Inubushi S; Sun YU; Lim H; Miyake K; Hongo A; Nomura T; Saitoh W; Moriya T; Tanino H; Hozumi C; Bouvet M; Singh SR; Endo I; Hoffman RM
Anticancer Res; 2020 May; 40(5):2509-2514. PubMed ID: 32366395
[TBL] [Abstract][Full Text] [Related]
9. Perifosine enhances bevacizumab-induced apoptosis and therapeutic efficacy by targeting PI3K/AKT pathway in a glioblastoma heterotopic model.
Ramezani S; Vousooghi N; Ramezani Kapourchali F; Joghataei MT
Apoptosis; 2017 Aug; 22(8):1025-1034. PubMed ID: 28616662
[TBL] [Abstract][Full Text] [Related]
10. VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab.
Di Stefano AL; Labussiere M; Lombardi G; Eoli M; Bianchessi D; Pasqualetti F; Farina P; Cuzzubbo S; Gallego-Perez-Larraya J; Boisselier B; Ducray F; Cheneau C; Moglia A; Finocchiaro G; Marie Y; Rahimian A; Hoang-Xuan K; Delattre JY; Mokhtari K; Sanson M
J Neurooncol; 2015 Feb; 121(3):499-504. PubMed ID: 25488073
[TBL] [Abstract][Full Text] [Related]
11. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q
Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543
[TBL] [Abstract][Full Text] [Related]
12. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
13. An isoflavone derivative potently inhibits the angiogenesis and progression of triple-negative breast cancer by targeting the MTA2/SerRS/VEGFA pathway.
Zhang X; Zou G; Li X; Wang L; Xie T; Zhao J; Wang L; Jiao S; Xiang R; Ye H; Shi Y
Cancer Biol Med; 2020 Aug; 17(3):693-706. PubMed ID: 32944400
[No Abstract] [Full Text] [Related]
14. miR-140-5p mediates bevacizumab-induced cytotoxicity to cardiomyocytes by targeting the
Chen XY; Huang WL; Peng XP; Lv YN; Li JH; Xiong JP
Toxicol Res (Camb); 2019 Nov; 8(6):875-884. PubMed ID: 32190292
[TBL] [Abstract][Full Text] [Related]
15. Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines.
Grepin R; Guyot M; Jacquin M; Durivault J; Chamorey E; Sudaka A; Serdjebi C; Lacarelle B; Scoazec JY; Negrier S; Simonnet H; Pages G
Oncogene; 2012 Mar; 31(13):1683-94. PubMed ID: 21909141
[TBL] [Abstract][Full Text] [Related]
16. Study of diffusion-weighted magnetic resonance imaging in the evaluation of the response to AAV2-VEGF-Trap neoadjuvant treatment in a triple-negative breast cancer animal model.
Li J; Zhu P; Wang L; Yang L; Zou L; Gao F
Cancer Med; 2019 Apr; 8(4):1594-1603. PubMed ID: 30900382
[TBL] [Abstract][Full Text] [Related]
17. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
Jin K; Pandey NB; Popel AS
Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment.
Ortholan C; Durivault J; Hannoun-Levi JM; Guyot M; Bourcier C; Ambrosetti D; Safe S; Pagès G
Eur J Cancer; 2010 Nov; 46(16):3022-36. PubMed ID: 20729074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
